1-20 of 190
Ottmann
Close
Sort by
Journal Articles

Diagnosis, prognostic factors, and assessment of ALL in adults: 2024 ELN recommendations from a European expert panel

Nicola Gökbuget, Nicolas Boissel, Sabina Chiaretti, Hervé Dombret, Michael Doubek, Adele Fielding, Robin Foà, Sebastian Giebel, Dieter Hoelzer, Mathilde Hunault, David I. Marks, Giovanni Martinelli, Oliver Ottmann, Anita Rijneveld, Philippe Rousselot, Josep Ribera, Renato Bassan
Journal: Blood
Blood (2024) 143 (19): 1891–1902.
https://doi.org/10.1182/blood.2023020794
Published: 2024
Includes: Supplemental data
Journal Articles

Management of ALL in adults: 2024 ELN recommendations from a European expert panel

Nicola Gökbuget, Nicolas Boissel, Sabina Chiaretti, Hervé Dombret, Michael Doubek, Adele Fielding, Robin Foà, Sebastian Giebel, Dieter Hoelzer, Mathilde Hunault, David I. Marks, Giovanni Martinelli, Oliver Ottmann, Anita Rijneveld, Philippe Rousselot, Josep Ribera, Renato Bassan
Journal: Blood
Blood (2024) 143 (19): 1903–1930.
https://doi.org/10.1182/blood.2023023568
Published: 2024
Includes: Supplemental data
Journal Articles

Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients (Pts) with Very High/High-Risk Myelodysplastic Syndrome (vHR/HR-MDS) and Acute Myeloid Leukemia (AML): Final Analysis from a Phase Ib Study

Andrew M. Brunner, Jordi Esteve, Kimmo Porkka, Steve Knapper, Elie Traer, Sebastian Scholl, Guillermo Garcia-Manero, Norbert Vey, Martin Wermke, Jeroen Janssen, Rupa Narayan, Sun Loo, Mika Kontro, Oliver Ottmann, Purushotham Naidu, Marc Pelletier, May Han, Andrew Lewandowski, Na Zhang, Anisa Mohammed, Mikael L. Rinne, Uma Borate, Andrew H. Wei, Natalia Tovar
Journal: Blood
Blood (2021) 138 (Supplement 1): 244.
https://doi.org/10.1182/blood-2021-146039
Published: 2021
Journal Articles

Arsenic Trioxide Suppresses Growth of BCR-ABL1 Positive Cells with "Gatekeeper" or Compound Mutation

Afsar Ali Mian, Hadiqa Raees, Sujjawal Ahmad, Oliver Ottmann, El-Nasir M A Lalani
Journal: Blood
Blood (2021) 138 (Supplement 1): 4346.
https://doi.org/10.1182/blood-2021-154511
Published: 2021
Journal Articles

PF-114 in Patients Failing Prior Tyrosine Kinase-Inhibitor Therapy Including BCR::ABL1 T315I

Anna G. Turkina, Olga Vinogradova, Elza Lomaia, Evgeniya Shatokhina, Oleg A. Shukhov, Andrey Zaritskey, Ekaterina Yu. Chelysheva, Dzhariyat Shikhbabaeva, Irina Nemchenko, Anna Petrova, Anastasiya Bykova, Vasily Shuvaev, Nadia Siordia, Jorge E. Cortes, Robert Peter Gale, Michele Baccarani, Oliver Ottmann, Ilya Mikhailov, Fedor Novikov, Veronika Shulgina, Ghermes Chilov
Journal: Blood
Blood (2021) 138 (Supplement 1): 1482.
https://doi.org/10.1182/blood-2021-150120
Published: 2021
Journal Articles

Sabatolimab (MBG453) Dose Selection and Dose-Response Analysis in Myelodysplastic Syndrome (MDS)/Acute Myeloid Leukemia (AML): Population Pharmacokinetics (PK) Modeling and Evaluation of Clinical Efficacy/Safety By Dose

Andrew H. Wei, MBBS, PhD, Jordi Esteve, Kimmo Porkka, Steve Knapper, Norbert Vey, MD, Sebastian Scholl, Guillermo Garcia-Manero, MD, Martin Wermke, Jeroen Janssen, Elie Traer, Sun Loo, Rupa Narayan, Natalia Tovar, Mika Kontro, Oliver Ottmann, Siyan Xu, Serena Liao, Andrew Stein, Fariba Khanshan, Purushotham Naidu, Na Zhang, Anisa Mohammed, Mikael L. Rinne, Haiying Sun, Andrew M. Brunner, MD, Uma Borate
Journal: Blood
Blood (2020) 136 (Supplement 1): 40–42.
https://doi.org/10.1182/blood-2020-137307
Published: 2020
Journal Articles

Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS): Updated Results from a Phase 1b Study

Andrew M. Brunner, MD, Jordi Esteve, Kimmo Porkka, Steve Knapper, Norbert Vey, MD, Sebastian Scholl, Guillermo Garcia-Manero, MD, Martin Wermke, Jeroen Janssen, Elie Traer, Sun Loo, Rupa Narayan, Natalia Tovar, Mika Kontro, Oliver Ottmann, Purushotham Naidu, Sema Kurtulus, Jessica Makofske, Serena Liao, Anisa Mohammed, Catherine A. Sabatos-Peyton, Mikael L. Rinne, Uma Borate, Andrew H. Wei, MBBS, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 1–2.
https://doi.org/10.1182/blood-2020-136855
Published: 2020
Journal Articles

TKI vs relapse after HSCT: is the jury still out?

Oliver G. Ottmann
Journal: Blood
Blood (2020) 136 (15): 1705–1706.
https://doi.org/10.1182/blood.2020007021
Published: 2020
Journal Articles

Phase Ib Study of the Anti-TIM-3 Antibody MBG453 in Combination with Decitabine in Patients with High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

Uma Borate, MD, Jordi Esteve, Kimmo Porkka, Steve Knapper, Norbert Vey, MD PhD, Sebastian Scholl, Guillermo Garcia-Manero, MD, Martin Wermke, MD, Jeroen Janssen, Elie Traer, Chong Chyn Chua, Rupa Narayan, Natalia Tovar, Mika Kontro, Oliver Ottmann, Prof, MD, Haiying Sun, Tyler Longmire, Sebastian Szpakowski, Serena Liao, Anuradha Patel, Mikael L Rinne, Andrew Brunner, MD, Andrew H. Wei, PhD FRACP, FRCPA, MBBS
Journal: Blood
Blood (2019) 134 (Supplement_1): 570.
https://doi.org/10.1182/blood-2019-128178
Published: 2019
Journal Articles

Interim Analysis of a Prospective Multicentre Study Using Next Generation Sequencing for Kinase Domain Mutational Analysis in CML Patients on First or Subsequent TKI Therapy

Hugues De Lavallade, Sophie Jackson, BSc, Heather Oakervee, BSc, MBBS, MD MRCP, FRCPath, Sebastian Francis, MBChB, MRCP, Edward Belsham, FRCPath, MB, Paul Cahalin, MA MRCP FRCPath, Joanne Ewing, PhDBMBS BSc FRPATH, Jenny Byrne, MD PhD, Kate Rothwell, BA MB BChir, PhD, Sandra Hassan, MBBS, MRCP, FRCPath, MDRes), Srinivas Pillai, MBBS,MD MRCP, FRCPath, Priyanka Mehta, Anshu Garg, MBBS,MDMRCP,FRCPath, Mhairi Copland, PhD MBBChir, FRCP, FRCPath, Oliver Ottmann, Prof, MD, Deepti Radia, Patrick Harrington, MRCP, FRCPath, Rachel Greig, Nicholas Lea, PhD, Michael Thompson, Aytug Kizilors, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2935.
https://doi.org/10.1182/blood-2019-129825
Published: 2019
Journal Articles

Activation of AKT/mTOR Pathway in Ph+ Acute Lymphoblastic Leukemia (ALL) Leads to Non-Mutational Resistance

Afsar Ali Mian, BSc, MPhil, PhD, Usva Zafar, BSc, Oliver Ottmann, Prof, MD, Martin Ruthardt, MD, El-Nasir M A Lalani, BSc MBChB FRCPath PhDFHEA
Journal: Blood
Blood (2019) 134 (Supplement_1): 2570.
https://doi.org/10.1182/blood-2019-130898
Published: 2019
Journal Articles

PF-114: A 4 th Generation Tyrosine Kinase-Inhibitor for Chronic Phase Chronic Myeloid Leukaemia Including BCRABL1 T315I

Anna G. Turkina, Prof., MD, Olga Vinogradova, MD PhD, Elza Lomaia, MD PhD, Evgeniya Shatokhina, MD PhD, Oleg A. Shukhov, MD PhD, Ekaterina Yu. Chelysheva, MD PhD, Dzhariyat Shikhbabaeva, Irina Nemchenko, MD PhD, Anna Petrova, MD, Anastasiya Bykova, MD, Andrey Zaritskey, MD PhD, Nadia Siordia, MD, Vasily Shuvaev, MD, Jorge E. Cortes, MD, Robert Peter Gale, Michele Baccarani, MD, Oliver Ottmann, Prof, MD, Ilya Mikhailov, Fedor Novikov, PhD, Veronika Shulgina, PhD MD, Ghermes Chilov, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1638.
https://doi.org/10.1182/blood-2019-127951
Published: 2019
Journal Articles

Phase-1 Study of PF-114 Mesylate in CML Failing Prior Tyrosine Kinase-Inhibitor Therapy

Anna G Turkina, Prof., MD, Olga Vinogradova, MD PhD, Elza Lomaia, MD, Evgeniya Shatokhina, MD PhD, Oleg Shukhov, MD PhD, Ekaterina Chelysheva, MD PhD, Irina Nemchenko, MD PhD, Anna Petrova, MD, Anastasiya Bykova, MD, Andrey Zaritskey, MD PhD, Nadia Siordia, MD, Dzhariyat Shikhbabaeva, Vasily Shuvaev, MD, Jorge E. Cortes, MD, Robert Peter Gale, Michele Baccarani, MD, Oliver G. Ottmann, MD, Ilya Mikhailov, Fedor Novikov, PhD, Veronika Shulgina, PhD MD, Ghermes Chilov, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 790.
https://doi.org/10.1182/blood-2018-99-116803
Published: 2018
Journal Articles

Phase I Study of the PTEFb Inhibitor BAY 1251152 in Patients with Acute Myelogenous Leukemia

Michael Byrne, MD, Mark G. Frattini, MD PhD, Oliver G. Ottmann, MD, Ioannis Mantzaris, MD MS, Martin Wermke, MD, Daniel J. Lee, MD, Daniel Morillo, MD, Arne Scholz, PhD, Stuart Ince, PhD, Ray Valencia, MD, Fabricio Souza, MD, Raul Cordoba, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4055.
https://doi.org/10.1182/blood-2018-99-117257
Published: 2018
Journal Articles

Subtractive Interaction Proteomics Reveal a Network of Signaling Pathways Activated By an Oncogenic Transcription Factor in High Risk AML

Claudia Chiriches, PhD, Nathalie Guillen, PhD, Michal Rokicki, Carol Guy, Afsar Mian, PhD, Oliver G. Ottmann, MD, Martin Ruthardt
Journal: Blood
Blood (2018) 132 (Supplement 1): 3917.
https://doi.org/10.1182/blood-2018-99-116631
Published: 2018
Journal Articles

Extracellular Microvesicle Cytokines Secreted from Bone Marrow Mesenchymal Cells Mediate Proliferative and Survival Advantage in Acute Myeloid Leukaemia

Michelle Lazenby, BSc, Oliver G. Ottmann, MD, Keith Wilson, FRCPath, MRCP, MBBS, Caroline Alvares, MBBS, PhD, Joanna Zabkiewicz, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2744.
https://doi.org/10.1182/blood-2018-99-113342
Published: 2018
Journal Articles

Adipogeneis in the Bone Marrow Microenvironment Confers a Proliferative Advantage in Residual Leukaemic Cell Populations in Acute Myeloid Leukaemia after Allogeneic Stem Cell Transplantation

Felicity May, BSc, Caroline Alvares, MBBS, PhD, Oliver G. Ottmann, MD, Joanna Zabkiewicz, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2580.
https://doi.org/10.1182/blood-2018-99-114443
Published: 2018
Journal Articles

Bone Marrow Stromal Cells Mediate Adhesion Based Drug Resistance in Acute Myeloid Leukaemia through Reciprocal Feedback of the β-Catenin/CD44 Signalling Axis

Lihui Zhuang, PhD MSc, BSc, Richard Darley, PhD, Oliver G. Ottmann, MD, Joanna Zabkiewicz, PhD, Caroline Alvares, MBBS, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2776.
https://doi.org/10.1182/blood-2018-99-113811
Published: 2018
Journal Articles

Nilotinib (Tasigna ® ) and Low Intensity Chemotherapy for First-Line Treatment of Elderly Patients with BCR-ABL1- Positive Acute Lymphoblastic Leukemia: Final Results of a Prospective Multicenter Trial (EWALL-PH02)

Oliver G. Ottmann, MD, Heike Pfeifer, MD, Jean-Michel Cayuela, PhD, Karsten Spiekermann, MD, Wolfram Jung, MD, Joachim Beck, Emmanuel Raffoux, MD, Pascal Turlure, MD, Chantal Himberlin, Francoise Huguet, MD, Andreas Viardot, MD, Knut Wendelin, MD, Albrecht Reichle, MD, Sébastien Maury, MD PhD, Laurence Sanhes, MD, Francoise Isnard, PhD, Jean-Yves Cahn, MD, Stephane Lepretre, Patrice Chevallier, MD, Martine Escoffre-Barbe, MD, Josep-Maria Ribera, MD PhD, Dieter Hoelzer, MD PhD, Nicola Goekbuget, MD, Hervé Dombret, Philippe Rousselot, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 31.
https://doi.org/10.1182/blood-2018-99-114552
Published: 2018
Journal Articles

Genomic CDKN2A/2B deletions in adult Ph + ALL are adverse despite allogeneic stem cell transplantation

Heike Pfeifer, Katharina Raum, Sandra Markovic, Verena Nowak, Stephanie Fey, Julia Obländer, Jovita Pressler, Verena Böhm, Monika Brüggemann, Lydia Wunderle, Andreas Hüttmann, Ralph Wäsch, Joachim Beck, Matthias Stelljes, Andreas Viardot, Fabian Lang, Dieter Hoelzer, Wolf-Karsten Hofmann, Hubert Serve, Christel Weiss, Nicola Goekbuget, Oliver G. Ottmann, Daniel Nowak
Journal: Blood
Blood (2018) 131 (13): 1464–1475.
https://doi.org/10.1182/blood-2017-07-796862
Published: 2018
Includes: Supplemental data